Get started
Author

Joshua Gahir

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2021 · Obbina Abani, Ali Abbas, et al. · The Lancet · 1,976
PDF
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2021 · Eugenia Abaleke, Mustafa Abbas, et al. · The Lancet · 533
PDF
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
2021 · Obbina Abani, Ali Abbas, et al. · The Lancet · 493
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2022 · Obbina Abani, Ali Abbas, et al. · The Lancet · 369
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis
2022 · Obbina Abani, Ali Abbas, et al. · The Lancet · 324
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2021 · Obbina Abani, Ali Abbas, et al. · The Lancet · 290
Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial
2023 · Obbina Abani, Ali Abbas, et al. · The Lancet · 129
Climate change, malaria and neglected tropical diseases: a scoping review
2024 · Petra Klepac, Jennifer L Hsieh, et al. · Transactions of the Royal Society of Tropical Medicine and Hygiene · 83
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2023 · O Abani, A Abbas, et al. · The Lancet Diabetes & Endocrinology · 41
PDF
Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial
2024 · Saul N Faust, Richard Haynes, et al. · The Lancet Child & Adolescent Health · 39
PDF
Neutralising immunity to omicron sublineages BQ.1.1, XBB, and XBB.1.5 in healthy adults is boosted by bivalent BA.1-containing mRNA vaccination and previous Omicron infection
2023 · Edward J Carr, Mary Y Wu, et al. · The Lancet Infectious Diseases · 29
PDF
COVID-19 in non-hospitalised adults caused by either SARS-CoV-2 sub-variants Omicron BA.1, BA.2, BA.4/5 or Delta associates with similar illness duration, symptom severity and viral kinetics, irrespective of vaccination history
2024 · Hermaleigh Townsley, Joshua Gahir, et al. · PLoS ONE · 15
PDF
Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2025 · O Abani, A Abbas, et al. · The Lancet Infectious Diseases · 12
PDF
Delayed healthcare seeking and prolonged illness in healthcare workers during the COVID-19 pandemic: a single-centre observational study
2020 · Angus de Wilton, Eliz Kilich, et al. · BMJ Open · 11
PDF
Real-time estimation of immunological responses against emerging SARS-CoV-2 variants in the UK: a mathematical modelling study
2024 · Timothy W Russell, Hermaleigh Townsley, et al. · The Lancet Infectious Diseases · 10
Independent SARS-CoV-2 staff testing protected academic and health-care institutions in northwest London
2023 · Chris Bailey, Theo Sanderson, et al. · The Lancet · 10
PDF
SARS-CoV-2 mucosal neutralising immunity after vaccination
2023 · Edward J Carr, Guilia Dowgier, et al. · The Lancet Infectious Diseases · 7
PDF
Demographics and Outcomes of Initial Phase of COVID-19 Medicines Delivery Units Across 4 UK Centers During Peak B1.1.529 Omicron Epidemic: A Service Evaluation
2022 · Michael Brown, Jasjot Saund, et al. · Open Forum Infectious Diseases · 7
PDF
Adults in Ghana generate higher and more durable neutralising antibody titres following primary course COVID-19 vaccination than matched UK adults: The HERITAGE Study
2025 · Eliza Mari Kwesi-Maliepaard, Yakubu Alhassan, et al. · BMC Medicine · 5
PDF
Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial
2025 · O. Abani, A. Abbas, et al. · EClinicalMedicine · 5
COVID-19 in non-hospitalised adults caused by either SARS-CoV-2 sub-variants Omicron BA.1, BA.2, BA.4/5 or Delta associates with similar illness duration, symptom severity and viral kinetics, irrespective of vaccination history.
2024 · Townsley, Hermaleigh, Gahir, Joshua, et al. · UCL Discovery (University College London) · 4
PDF
Third exposure to COVID-19 infection or vaccination differentially impacts T cell responses
2025 · Gift Ahimbisibwe, David Greenwood, et al. · Journal of Infection · 3
PDF
Chronogram: an R package for data curation and analysis of infection and vaccination cohort studies
2024 · David Greenwood, Marianne Shawe-Taylor, et al. · Bioinformatics Advances · 3
34 COVID-19 caused by either Omicron sub-variants or Delta in non-hospitalised adults associates with similar illness duration, symptom severity and viral kinetics, irrespective of vaccination history
2023 · Hermaleigh Townsley, Joshua Gahir, et al. · Clinical Infection in Practice · 2
28 Experiences of using Paxlovid to treat clinically extremely vulnerable non-hospitalised patients with COVID-19
2022 · Joshua Gahir, Jasjot Saund, et al. · Clinical Infection in Practice · 1
PDF
Works count: 28
Citation count: 2,322
H-index: 10
I10-index: 12
Year
Topic
Type